» Articles » PMID: 38561826

The Senescence Journey in Cancer Immunoediting

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2024 Apr 2
PMID 38561826
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in the tumor microenvironment can also promote tumor progression favoring the outgrowth of cancers capable of escaping immune control, in a process termed cancer immunoediting. This process, which has been classified into three phases, i.e. "elimination", "equilibrium" and "escape", is influenced by several cancer- and microenvironment-dependent factors. Senescence is a cellular program primed by cells in response to different pathophysiological stimuli, which is based on long-lasting cell cycle arrest and the secretion of numerous bioactive and inflammatory molecules. Because of this, cellular senescence is a potent immunomodulatory factor promptly recruiting immune cells and actively promoting tissue remodeling. In the context of cancer, these functions can lead to both cancer immunosurveillance and immunosuppression. In this review, the authors will discuss the role of senescence in cancer immunoediting, highlighting its context- and timing-dependent effects on the different three phases, describing how senescent cells promote immune cell recruitment for cancer cell elimination or sustain tumor microenvironment inflammation for immune escape. A potential contribution of senescent cells in cancer dormancy, as a mechanism of therapy resistance and cancer relapse, will be discussed with the final objective to unravel the immunotherapeutic implications of senescence modulation in cancer.

Citing Articles

The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.

Wang J, Shao F, Yu Q, Ye L, Wusiman D, Wu R Research (Wash D C). 2025; 8:0612.

PMID: 40046513 PMC: 11880593. DOI: 10.34133/research.0612.


Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment.

He L, Wan M, Yang X, Meng H Discov Oncol. 2025; 16(1):257.

PMID: 40024975 PMC: 11872995. DOI: 10.1007/s12672-025-01997-3.


Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


Cellular senescence in the tumor with a bone niche microenvironment: friend or foe?.

Alavimanesh S, Nayerain Jazi N, Choubani M, Saeidi F, Afkhami H, Yarahmadi A Clin Exp Med. 2025; 25(1):44.

PMID: 39849183 PMC: 11759293. DOI: 10.1007/s10238-025-01564-8.


Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.

Hamza F, Mohammad K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770433 PMC: 11679356. DOI: 10.3390/ph17121591.


References
1.
Sikora E, Czarnecka-Herok J, Bojko A, Sunderland P . Therapy-induced polyploidization and senescence: Coincidence or interconnection?. Semin Cancer Biol. 2020; 81:83-95. DOI: 10.1016/j.semcancer.2020.11.015. View

2.
Guan X, LaPak K, Hennessey R, Yu C, Shakya R, Zhang J . Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth. Mol Cancer Res. 2017; 15(3):237-249. PMC: 5334447. DOI: 10.1158/1541-7786.MCR-16-0319. View

3.
Roberson R, Kussick S, Vallieres E, Chen S, Wu D . Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 2005; 65(7):2795-803. DOI: 10.1158/0008-5472.CAN-04-1270. View

4.
Omer A, Di Marco S, Gallouzi I . The senescence-associated secretory phenotype as a driver of tumor growth: does G3BP1 hold the key?. Mol Cell Oncol. 2021; 8(1):1850161. PMC: 7849692. DOI: 10.1080/23723556.2020.1850161. View

5.
Georgilis A, Klotz S, Hanley C, Herranz N, Weirich B, Morancho B . PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells. Cancer Cell. 2018; 34(1):85-102.e9. PMC: 6048363. DOI: 10.1016/j.ccell.2018.06.007. View